WatchWell: Simple and Practical Strategies to Reduce the Negative Health Impact of Sedentary Screen Time

Arizona State University30 enrolled

Overview

The purpose of this study is to determine the feasibility, acceptability, efficacy, and participant adherence in using home-based technologies and wearable devices and simple, practical strategies to reduce the negative impact that evening screen time may have on your health.

Sedentary screen time (SST) is the most common discretionary activity among all US age and race/ethnic groups. SST is associated with poor health outcomes, including cardiovascular disease (CVD). Recreational SST (rSST) is 2-3X more detrimental to health than other forms of sedentary behavior (e.g., workplace sitting, traveling). Elucidating the mechanisms that lead to elevated harm resulting from rSST is critical. Impact of the COVID-19 pandemic to increase rSST amplifies the urgency of understanding rSST-related mechanisms that lead to detrimental health outcomes. Previous SST studies are limited in scope of intervention and outcomes. There are vital gaps in knowledge about how rSST and rSST-associated behaviors lead to increased CVD risk. Interventions applied in ecologically valid, real-world settings are urgently needed to develop the most potent interventions that address and attenuate critical mechanistic pathways that mediate rSST-associated health risks. WatchWell is a pilot study designed to achieve three important goals that will support our obtaining funding for this research and is responsive to reviewer comments on our previously submitted NIH/NHLBI P01 Program Project: 1) demonstrate feasibility and participant acceptability of study design 2) demonstrate participant acceptability of measurement devices; 3) generate preliminary data to estimate outcome effect sizes. In the course of WatchWell, the team of investigators will intervene on 3 behavioral mechanisms that are likely primary drivers of dSST CVD risk based on their prominent co-occurrence with rSST and individual contributions to CVD risk: blue light at night, nighttime food intake and prolonged evening sitting time. The investigators hypothesize that these 3 behavioral mechanisms impact CVD risk via downstream biological mechanisms including diurnal sleep/wake and body temperature rhythms, glucose metabolism, and autonomic balance (including heart rate variability, HRV). These biological mechanisms have not been assessed concurrently nor in the real-time, real-world context of rSST-related behaviors. For this WorkWell pilot, the team of investigators will test 2 of the 3 behavioral mechanisms compared to the baseline control condition per participant using a 3-condition randomized controlled crossover design. \[In the full trial to be resubmitted to the NIH, we will conduct a 4-condition crossover RCT, testing all 3 behavioral mechanisms compared to the baseline control condition per participant.\] The investigators will recruit adults with overweight and at least 2 criteria of the metabolic syndrome (goal of N=18 completers, up to 30 enrollees total), who have elevated CVD risk. Impact. Recreational SST is a highly prevalent, modifiable risk factor for CVD. WorkWell will be the first to intervene on rSST-associated evening/nighttime blue light, food intake, and prolonged sitting in a real-world setting and to concurrently measure downstream CVD-related biological mechanisms. The WorkWell study design is informed by and will contribute to the translational application of circadian biology. Aim 1. Assess the study feasibility and participant acceptability of delivering three behavioral strategies (avoiding dietary intake after 8p; blocking blue-light exposure after 8p; and breaking up prolonged sitting with standing after 5p) to reduce negative health exposures associated with rSST over two-week conditions in a randomized crossover study design. Aim 2. Assess protocol compliance and participant acceptability of a suite of wearable sensors and home-based technologies during the feasibility trial. Aim 3. Assess the preliminary efficacy and estimate effect size of the three behavioral strategies for improving postprandial glucose metabolism (primary focus on post-dinner meal, postprandial period), related 24-hr behaviors (sleep, other sedentary time, physical activity), heart rate variability, and circadian rhythms (sleep/wake activity rhythms, surface body temperature rhythms).

Conditions

Sedentary Time Cardiovascular Diseases Prediabetes Obesity

Interventions

Blue lightBEHAVIORAL

Blue light blocking glasses use and discouraged late night eating.

EatingBEHAVIORAL

Encouraged not to eat past 8pm.

StandingBEHAVIORAL

Encouraged to stand for 10 minutes per hour each out from 5pm to bed time.

Eligibility

Sex: ALLMin age: 26 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria * ≥26 years of age * BMI ≥ 27 kg/m2\*; ≥25 kg/m2, if Asian (full or multiple race)\*\* * Insufficiently active (per US National Guidelines for Physical Activity of 150 minutes of MVPA/Week) * Reporting an average of ≥3 hours of recreational sedentary screen time (rSST) per day, that usually extends at least until 9:00pm. * On a typical night, consumes calories (food and/or drink) after 8:00pm. * Meet at least 2 criteria for metabolic syndrome * Central adiposity: waist circumference \>40 inches (men); \>35 inches (women) * Elevated blood pressure: SBP \>130 mmHg and/or DBP \>85 mmHg OR controlled with medication * Low high density lipoprotein (HDL) cholesterol: \<40 mg/dL (men); \<50 mg/dL (women) * Elevated triglycerides: \>150 mg/dL OR controlled with medication * Elevated fasting glucose: ≥100 mg/dL OR controlled with medication Exclusion Criteria * Conditions related to sleep disruption, including lactation, pregnancy, mid-night care providers, sleep disorders, severe sleep apnea * History of hypoglycemia * Pacemaker * Caffeine consumption in excess and/or after 5pm (excess equals \>4 cups of coffee per day or equivalent) * Involvement in other physical activity, diet, or weight loss programs/studies * Weight change of 5% up or down in the last three months. * Drug abuse * THC use (smoking, edibles) * Excessive alcohol use (for women, 8 or more drinks per week; for men, 15 or more drinks per week) * Current smoker or user of any nicotine source - any amount or form (vapor/e-cig/tobacco/patch, gum, etc.) * Medications that markedly impact glucose metabolism and sleep (insulin, corticosteroids, growth hormone, melatonin) * Previous or current diagnosis of a clinical eating disorder (e.g., night eating syndrome, anorexia, bulimia, binge eating disorder); or self-report eating disorder behaviors * Unstable or poorly controlled blood glucose (e.g., hypoglycemia, fasting glucose greater than 125 mg/dL) * Chronic illness that may be associated with weight change (HIV/AIDS, active cancer, or uncontrolled thyroid disease) * Shift work * Recent or upcoming jetlag (travel 3 months prior and during study that is \>1 time zone away from Arizona) * Current practice of evening and nighttime blue light blocking. * Poorly controlled hypertension (SBP ≥165 or DBP ≥100) * Any condition or circumstance that would prevent compliance to the protocol * Use non-android phone as their primary/personal phone

Locations (1)

Arizona State University

Tempe, Arizona, United States

RECRUITING

Outcomes

Primary Outcomes

Treatment acceptability

Intervention acceptability will be assessed using the Treatment Evaluation Questionnaire (TEQ) to measure acceptability of the three experimental conditions following the completion of each condition. Scale Range: 0 to 4. Higher scores indicate greater acceptability.

Time frame: 2 weeks

Changes in Evening Sedentary Screen Time

Minutes per week of screen time after 5p as measured by WatchWell app and activPAL

Time frame: 2 weeks

Change in evening postprandial glycemic control (5pm - 5am)

Participants will be asked to wear the Dexcom G6 Pro continuous glucose monitor during baseline and experimental conditions. Glycemic control will be calculated by averaging all glucose readings from 5pm - 5am during each of the conditions.

Time frame: 2 weeks

Central Contacts

Dorothy Sears, PhD

CONTACT

602-496-3351 dsbanks@asu.edu

Jen Jondac, BS

CONTACT

602-543-6551 jenjondac@asu.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.